伊立替康联合雷替曲塞3周方案二线治疗晚期结直肠癌的疗效观察

Clinical observation of the 3-week schedule of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer

目的:观察伊立替康联合雷替曲塞二线治疗晚期结直肠癌的疗效及安全性。方法:对22例一线治疗失败的晚期结直肠癌病人予以二线治疗:伊立替康180 mg/m^2,静脉滴注1 h,第1天;雷替曲塞3 mg/m^2,静脉滴注15 min,第2天;21 d为1个周期。每2个周期评价疗效,并分析其安全性。结果:22例病人均可评价近期疗效,其中完全缓解1例,部分缓解4例,疾病稳定11例,疾病进展6例,客观有效率为22.7%,疾病控制率为72.7%,病人的中位肿瘤进展时间为5.0个月,中位总生存时间11.8个月。严重不良反应为中性粒细胞减少和腹泻,发生率分别为13.6%和4.5%。结论:伊立替康联合雷替曲塞在晚期结直肠癌的二线化疗中,有效率较高,不良反应能够耐受,值得在临床上推广。

Objective：To observe the efficacy and safety of irinotecan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer. Methods： Twenty-two patients with advanced colorectal cancer were treated with the second-line chemotherapy after the first-line treatment failure. The patients were treated with 180 mg/m^2 of irinotecan by intravenous infusion for 1 h on the first day,and 3 mg/m^2 of rahitrexed by intravenous infusion for 15 minutes on the second day,21 days as a cycle. The efficacy and safety were evaluated every 2 cycles. Results ： The short-term efficacy of all cases was evaluated. The complete response in 1 case, partial response in 4 cases, stable disease in 11 cases and progressive disease in 6 cases were found. The objective response and disease control rates were 22.7% and 72.7% ,respectively. The median time of tumor progression and median overall survival time were 5.0 and 11.8 months, respectively. The neutrophilopenia and diarrhea were serious adverse reactions, the incidence rates of those were 13.6% and 4.5% , respectively. Conclusions： The irinotccan combined with raltitrexed in the second-line chemotherapy of advanced colorectal cancer is high efficacy, and the adverse reactions can be tolerated, which is worthy of wider application.